PRN: Global Hepatitis Drugs Market 2017-2023: HCV Drugs Segment Comprised More than 84% of the $78.67 Billion Industry - Research and Markets

17/mar/2017 12.14.24 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Hepatitis Drugs Market 2017-2023: HCV Drugs Segment Comprised More than 84% of the $78.67 Billion Industry - Research and Markets

 
[17-March-2017]
 

DUBLIN, Mar. 17, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Hepatitis Drugs Market - Drivers, Opportunities, Trends, and Forecasts: 2017-2023" report to their offering.

Research and Markets Logo

The Hepatitis Drugs Market to Grow at a CAGR of 15.0% During the Forecast Period 2017-2023 to Aggregate $78.67 Billion By 2023

Factors such as rise in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.

The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.

Key Topics Covered:

1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
1.3 Pest Analysis

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Total Addressable Market (TAM)
3.2 Disease Overview
3.2.1 Hepatitis A
3.2.2 Hepatitis B
3.2.3 Hepatitis C
3.2.4 Hepatitis D
3.2.5 Hepatitis E
3.3 Disease Transmission
3.4 Related Markets

4 Market Outlook
4.1 Overview
4.2 Regulatory Bodies & Standards
4.3 Porter 5 (Five) Forces

5 Market Characteristics
5.1 Evolution
5.2 ROADMAP
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Demand of Hepatitis Drugs
5.3.1.2 Focus on Advanced DAAs
5.3.1.3 Introduction of IFN-free Therapies
5.3.1.4 Growth of Injection Drug Users
5.3.2 Restraints
5.3.2.1 Long Approva! l Process and Stringent Regulations
5.3.2.2 Side Effects of Hepatitis Drugs
5.3.2.3 Increase in the Number of Generic Drugs
5.3.2.4 Increasing Market Competition
5.3.3 Opportunities
5.3.3.1 Significant Increase in Mergers and Acquisitions
5.3.3.2 Emergence of Combination Drugs
5.3.3.3 Preventive Healthcare
5.3.3.4 Focus of Companies on Emerging Market
5.3.4 DRO - Impact Analysis

6 Trends, Roadmap and Projects
6.1 Market Trends & Impact
6.2 Technology Roadmap

7 Types: Market Size & Analysis

8 Trending Hepatitis Drugs
8.1 Overview
8.1.1 VEMLIDY
8.1.2 EPCLUSA
8.1.3 SOVALDI
8.1.4 INCIVEK
8.1.5 OLYSIO
8.1.6 VICTRELIS
8.1.7 VIREAD
8.1.8 HEPSERA
8.1.9 BARACLUDE
8.1.10 TYZEKA
8.1.11 INTRON A
8.1.12 PEGASYS
8.1.! 13 PEGINTRON
8.1.14 ! ROFERON- A
8.1.15 VIRAFERONPEG
8.1.16 REBETOL

9 Regions: Market Size & Analysis
9.1 OVERVIEW
9.1.1.1 Global Hepatitis Drugs Market by Geographical Segmentation

10 Vendor Scenario
10.1 Market Share Ranking 2016
10.1.1 GILEAD SCIENCES INC.
10.1.1.1 Sovaldi (sofosbuvir)
10.1.1.2 Harvoni (ledipasvir and sofosbuvir)
10.1.1.3 Viread (tenofovir disoproxil fumarate)
10.1.1.4 Hepsera (adefovir dipivoxil)
10.1.2 ABBVIE INC.
10.1.2.1 Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir)
10.1.3 JOHNSON & JOHNSON
10.1.3.1 Olysio (simeprevir)
10.1.3.2 Incivo(telaprevir)
10.1.4 MERCK & CO. INC.
10.1.4.1 Zepatier (elbasvir and grazoprevir)
10.1.4.2 Victrelis (boceprevir)
10.1.4.3 Peg-Intron (peginterferon alfa-2b)
10.1.4.4 Rebetol (ribavirin)
10.1.4.5 Intron A (interferon alfa-2b, recombinant) 10.1.5 GLAXOSMITHKLINE PLC
10.1.5.1 Pediarix Vaccine
10.1.5.2 Twinrix
10.1.5.3 Havrix
10.1.5.4 Epivir (lamivudine)
10.1.6 VERTEX PHARMACEUTICALS INC.
10.1.6.1 Incivek (telaprevir)
10.1.7 NOVARTIS AG
10.1.7.1 Tyzeka (telbivudine)
10.1.8 HOFFMANN-LA ROCHE LTD.
10.1.8.1 Pegasys (peginterferon alfa-2a)

11 Vendor Profiles
11.1.1 Merck & Co. Inc.
11.1.2 Hoffmann-La Roche Ltd.
11.1.3 Gilead Sciences
11.1.4 Novartis AG
11.1.5 GlaxoSmithKline plc

12 Global Generalist
12.1 Vertex Pharmaceuticals Inc.
12.2 Johnson & Johnson

13 Market Landscape
13.1 Market Landscape
13.1.1 Mergers & Acquisitions (M&A)

For more information about this report visit http://www.researchandmarkets.com/research/b6bz53/global_hepatitis

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl